Related Experiment Videos
Erythropoietin claims monitoring policy: implications of the October 2006 update continuing
1St. Joseph Hospital Renal Services, Orange, CA, USA.
The Centers for Medicare and Medicaid Services issued a revised erythropoietin claims monitoring policy that governs reimbursement for Epoetin alfa and darbepoetin alfa in patients on dialysis effective October 1, 2006. The new policy reinforces the upper Hb target level of 12.0 g/dL. However, the new provisions also allow increased latitude for making timely dose adjustments in response to the variability in Hb levels that occurs due to changes in patient status.
The Centers for Medicare and Medicaid Services issued a revised erythropoietin claims monitoring policy that governs reimbursement for Epoetin alfa and darbepoetin alfa in patients on dialysis effective October 1, 2006. The new policy reinforces the upper Hb target level of 12.0 g/dL. However, the new provisions also allow increased latitude for making timely dose adjustments in response to the variability in Hb levels that occurs due to changes in patient status.
Related Concept Videos
Factors Affecting Erythropoiesis
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...
Therapeutic Drug Monitoring: Affecting Factors
Erythropoiesis
Erythropoiesis
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
Therapeutic Drug Monitoring: Overview and Classification